RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
基于RIG-I的免疫疗法可提高临床前AML模型中的生存率,并使AML细胞对检查点阻断疗法更加敏感。
期刊:Leukemia
影响因子:13.4
doi:10.1038/s41375-019-0639-x
Ruzicka, Michael; Koenig, Lars M; Formisano, Simone; Boehmer, Daniel F R; Vick, Binje; Heuer, Eva-M; Meinl, Hanna; Kocheise, Lorenz; Zeitlhöfler, Marcus; Ahlfeld, Julia; Kobold, Sebastian; Endres, Stefan; Subklewe, Marion; Duewell, Peter; Schnurr, Max; Jeremias, Irmela; Lichtenegger, Felix S; Rothenfusser, Simon